On June 2, 2020 YiChang HEC ChangJiang Pharmaceutical Co., Ltd (1558.HK) obtained a formal Approval Letter from the China Securities Regulatory Commission (CSRC) in relation to the application by the Company to the CSRC in respect of the full circulation of H Shares. HEC Pharmaceutical was one of the first two companies that obtained the formal Approval Letter after CSRC promoted H Share full circulation reform last year.
Huatai Financial was the Sole Financial Advisor for the deal. Pursuant to the CSRC Approval, 226,200,000 domestic unlisted shares (‘‘Domestic Shares’’) held by Guangdong HEC Technology Holding Co., Ltd., a shareholder of the Company, could be converted into overseas listed shares (‘‘H Shares’’). Such shares will be allowed to be listed on the Hong Kong Stock Exchange upon completion of the conversion.
HEC Pharmaceutical is a pharmaceutical manufacturing company that focuses on the development, manufacturing and sale of pharmaceutical products in the therapeutic areas of anti-virus, endocrine diseases and cardiovascular diseases. The Company is the domestic pharmaceutical manufacturing platform of the HEC Group.